OpenNashEarnings

Medical Devices · NYSE: RMD

ResMed earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends June · next results expected around 28 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q1 FY2027

ResMed closed the MatrixCare divestiture and launched the AirTouch F40 fabric mask, refocusing on core sleep and breathing health and its connected digital ecosystem.

ResMed's quarter was driven by demand for sleep devices and masks in both the Americas and the rest of the world. It launched the AirTouch F40, its third fabric mask, plus the AirCurve 11 ST/ST-A bilevel device in the U.S. It also closed the MatrixCare sale and added partnerships with Eight Sleep and ŌURA to bring more people into sleep care.

Read the Q1 FY2027 summary →Q1 FY2027 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$1.4B+5.9% y/yQ1 FY27
Q2 FY25: $1.3BQ2 25$1.3BQ3 FY25: $1.3BQ3 25$1.3BQ4 FY25: $1.3B (worked out from the annual figure)Q4 25$1.3BQ1 FY26: $1.3BQ1 26$1.3BQ2 FY26: $1.4BQ2 26$1.4BQ3 FY26: $1.4BQ3 26$1.4BQ4 FY26: $1.5B (worked out from the annual figure)Q4 26$1.5BQ1 FY27: $1.4BQ1 27$1.4B

Fourth quarter worked out from the annual figure.

Data
Q2 FY25$1.3B
Q3 FY25$1.3B
Q4 FY25$1.3B *
Q1 FY26$1.3B
Q2 FY26$1.4B
Q3 FY26$1.4B
Q4 FY26$1.5B *
Q1 FY27$1.4B
Diluted EPS (GAAP)$2.92+23.2% y/yQ1 FY27
Q2 FY25: $2.34Q2 25$2.34Q3 FY25: $2.48Q3 25$2.48Q1 FY26: $2.37Q1 26$2.37Q2 FY26: $2.68Q2 26$2.68Q3 FY26: $2.74Q3 26$2.74Q1 FY27: $2.92Q1 27$2.92
Data
Q2 FY25$2.34
Q3 FY25$2.48
Q1 FY26$2.37
Q2 FY26$2.68
Q3 FY26$2.74
Q1 FY27$2.92

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin32.0%−1.4 pts y/yQ1 FY27
Q2 FY25: 32.5%Q2 2532.5%Q3 FY25: 33.0%Q3 2533.0%Q4 FY25: 33.7%Q4 2533.7%Q1 FY26: 33.4%Q1 2633.4%Q2 FY26: 34.6%Q2 2634.6%Q3 FY26: 34.9%Q3 2634.9%Q4 FY26: 30.7%Q4 2630.7%Q1 FY27: 32.0%Q1 2732.0%
Data
Q2 FY2532.5%
Q3 FY2533.0%
Q4 FY2533.7%
Q1 FY2633.4%
Q2 FY2634.6%
Q3 FY2634.9%
Q4 FY2630.7%
Q1 FY2732.0%
Free cash flow$373.7M−9.8% y/yQ1 FY27
Q2 FY25: $288.0MQ2 25$288.0MQ3 FY25: $557.9MQ3 25$557.9MQ4 FY25: $508.2MQ4 25$508.2MQ1 FY26: $414.4MQ1 26$414.4MQ2 FY26: $311.2MQ2 26$311.2MQ3 FY26: $520.5MQ3 26$520.5MQ4 FY26: $403.5MQ4 26$403.5MQ1 FY27: $373.7MQ1 27$373.7M
Data
Q2 FY25$288.0M
Q3 FY25$557.9M
Q4 FY25$508.2M
Q1 FY26$414.4M
Q2 FY26$311.2M
Q3 FY26$520.5M
Q4 FY26$403.5M
Q1 FY27$373.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue$1.3B$1.3B$1.3Bd$1.3B$1.4B$1.4B$1.5Bd$1.4B
Gross margin58.6%59.3%60.8%61.2%61.8%62.2%58.8%61.5%
Operating income$417.2M$426.3M$454.5Md$446.5M$491.7M$499.8M$448.7Md$453.0M
Operating margin32.5%33.0%33.7%33.4%34.6%34.9%30.7%32.0%
Net income$344.6M$365.0M$379.7Md$348.5M$392.6M$398.7M$383.4Md$418.4M
Diluted EPS$2.34$2.48—$2.37$2.68$2.74—$2.92
Operating cash flow$308.6Md$578.7Md$538.8Md$457.3M$339.7Md$554.1Md$454.6Md$422.4M
Capital expenditure$20.6Md$20.8Md$30.6Md$43.0M$28.5Md$33.7Md$51.1Md$48.7M
Free cash flow$288.0M$557.9M$508.2M$414.4M$311.2M$520.5M$403.5M$373.7M
R&D expense$81.4M$83.9M$86.4Md$89.5M$91.0M$94.3M$105.7Md$102.9M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings